The host-tumor immune conflict: from immunosuppression to resistance and destruction (Q41633001)

5 October 2017

1 reference

title

The host-tumor immune conflict: from immunosuppression to resistance and destruction (English)

1 reference

5 October 2017

1 reference

5

1 reference

5 October 2017

Chouaib S

1

1 reference

5 October 2017

Asselin-Paturel C

series ordinal

2

1 reference

5 October 2017

Mami-Chouaib F

series ordinal

3

1 reference

5 October 2017

Caignard A

series ordinal

4

1 reference

5 October 2017

1 October 1997

1 reference

5 October 2017

1 reference

5 October 2017

18

1 reference

5 October 2017

10

1 reference

5 October 2017

493-497

1 reference

Identification of human cancers deficient in antigen processing

5 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Costimulation of T cells for tumor immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Cytokines, tumour-cell death and immunogenicity: a question of choice

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Maintenance of clonal anergy by endogenously produced IL-10

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Inflammatory and immunomodulatory roles of TGF-beta.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Inhibition of cytokine production by cyclosporin A and transforming growth factor beta

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

1 reference

7 January 2021

The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

The origin and function of tumor-associated macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Perforin-mediated target cell lysis by cytolytic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Interleukin-6 functions as an intracellular growth factor in hairy cell leukemia in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Alteration of the sphingomyelin/ceramide pathway is associated with resistance of human breast carcinoma MCF7 cells to tumor necrosis factor-alpha-mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Impairment of Fas-antigen expression in adriamycin-resistant but not TNF-resistant MCF7 tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

The role of FasL-induced apoptosis in immune privilege

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Fas ligand in human serum

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901115-8

7 January 2021

10.1016/S0167-5699(97)01115-8

Identifiers

DOI

1 reference

5 October 2017

1 reference